Clinical trials in Cyprus – page 2

Clinical research in Cyprus encompasses investigations into myasthenia gravis and idiopathic inflammatory myopathy, focusing on novel therapeutic approaches for patients with these challenging conditions. These trials evaluate both intravenous and subcutaneous formulations of targeted therapies, including studies specifically designed for patients who are seronegative for certain antibodies. The research aims to improve treatment outcomes and quality of life for individuals living with these debilitating neuromuscular disorders.

• Assessment of efgartigimod formulations in generalized and ocular myasthenia gravis
• Long-term safety and efficacy evaluation in active inflammatory myopathy
• Treatment options for antibody-seronegative patient populations
• Subcutaneous administration methods for improved patient convenience

These investigations represent important contributions to understanding how targeted immunomodulatory therapies can address the underlying mechanisms of neuromuscular diseases, potentially offering new hope for patients who have limited treatment options.

Research efforts in Cyprus include significant focus on hereditary transthyretin-mediated amyloidosis, particularly forms affecting the peripheral nervous system. These studies investigate innovative RNA-based therapeutic approaches designed to reduce the production of abnormal proteins that cause progressive nerve damage. The trials assess both the effectiveness in halting neurologic deterioration and the long-term safety profiles of these novel interventions.

• Evaluation of ALN-TTRSC02 and nucresiran in hereditary amyloidosis with polyneuropathy
• Assessment of neurologic impairment and disease progression
• Extended dosing safety studies with eplontersen
• Global collaboration in rare genetic disease research

This research addresses a critical need for effective treatments in rare hereditary conditions, where early intervention may significantly alter the disease trajectory and preserve neurological function.

Cyprus participates in advanced breast cancer research focusing on hormone receptor-positive disease. Clinical trials examine novel endocrine therapies for patients with early-stage disease who show evidence of circulating tumor DNA, indicating potential for recurrence. These investigations also address quality of life concerns, specifically targeting the musculoskeletal symptoms that commonly arise from endocrine therapy and can significantly impact treatment adherence.

• Evaluation of elacestrant versus standard endocrine therapy in ER-positive, HER2-negative breast cancer
• Studies on preventing distant metastasis in ctDNA-positive patients
• Supportive care interventions for endocrine therapy-related symptoms
• Management of arthralgias, myalgias, and bone pain in breast cancer survivors

These trials represent a comprehensive approach to breast cancer care, addressing both disease control and the maintenance of patient well-being throughout treatment.

Innovative research in prostate cancer conducted in Cyprus explores the integration of advanced imaging technologies with treatment planning. Studies investigate the use of PSMA PET/CT imaging combined with artificial intelligence systems to personalize radiotherapy approaches. Additionally, trials examine targeted radionuclide therapy for patients with early metastatic disease, aiming to delay disease progression while minimizing treatment burden.

• Artificial intelligence-driven radiotherapy personalization
• Lutetium-177-PSMA radioligand therapy in oligometastatic disease
• Ultra-hypofractionated radiation with optimized hormonal therapy duration
• Comparison of active treatment versus deferred androgen deprivation

This research represents a shift toward precision medicine in prostate cancer, utilizing molecular imaging and computational tools to tailor treatments to individual patient characteristics.

Clinical investigations in Cyprus include studies on retroperitoneal sarcomas, specifically high-risk leiomyosarcoma and liposarcoma. These trials evaluate whether preoperative chemotherapy can improve outcomes when combined with curative-intent surgery. The research addresses a significant gap in treatment strategies for these rare and challenging malignancies, where optimal therapeutic approaches remain under investigation.

• Assessment of preoperative chemotherapy in high-risk retroperitoneal sarcomas
• Evaluation of disease-free survival outcomes
• Studies on dedifferentiated liposarcoma and leiomyosarcoma
• International collaboration in rare tumor research

These investigations are particularly important given the rarity of these tumors and the need for evidence-based treatment protocols that can guide clinical decision-making.

Cyprus participates in platform trials designed to efficiently evaluate treatments for acute respiratory infections, including COVID-19. These adaptive trials assess various therapeutic interventions and strategies for hospitalized adults, focusing on improving clinical recovery and outcomes. The research infrastructure allows for rapid evaluation of multiple treatment approaches within a single coordinated framework.

• Platform trial design for respiratory infection treatments
• Evaluation of immune modulation strategies in COVID-19
• Assessment of clinical recovery and safety outcomes
• Multicenter collaboration in infectious disease research

This approach enables more efficient clinical research during public health emergencies, allowing for faster identification of effective treatments while maintaining rigorous scientific standards.

Research in Cyprus includes evaluation of novel immunotherapy combinations for advanced solid tumors. Studies investigate fixed-dose combinations of immune checkpoint inhibitors, assessing their safety profiles and pharmacokinetic properties in patients with locally advanced, recurrent, or metastatic cancers. These trials contribute to understanding optimal dosing strategies and administration methods for cancer immunotherapy.

• Safety and pharmacokinetics of tiragolumab and atezolizumab combination
• Intravenous fixed-dose combination formulations
• Studies in advanced and metastatic solid tumors
• Evaluation of novel immune checkpoint inhibitor approaches

These investigations represent ongoing efforts to expand and refine immunotherapy options for cancer patients, potentially offering more convenient administration methods and improved treatment outcomes.

Clinical trials in Cyprus address opioid use disorder through investigation of adjunctive pharmacological interventions. Research evaluates whether ketamine can reduce depressive symptoms and prevent relapse in individuals receiving maintenance treatment with methadone or buprenorphine/naloxone. This work addresses the complex interplay between addiction, mental health, and treatment outcomes.

• Efficacy of ketamine in opioid use disorder treatment
• Depression symptom reduction in maintenance therapy patients
• Relapse prevention strategies
• Integration of mental health treatment with addiction care

These studies reflect growing recognition of the need for comprehensive approaches to substance use disorders that address both addiction and co-occurring mental health conditions.